Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Copland

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Clinical and Experimental Immunology|November 18, 2003
No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infectionsD C Kilpatrick, L A McLintock, E K Allan, et al.
Leukemia|December 2, 2015
Mtss1 is a critical epigenetically regulated tumor suppressor in CMLM Schemionek, O Herrmann, M M Reher, et al.
Leukemia|January 12, 2020
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual diseaseG A Horne, J Stobo, C Kelly, et al.
Kidney International|July 22, 2011
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal TrialMichael V Rocco, Robert S Lockridge, Gerald J Beck, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Clinical and Experimental Immunology|November 18, 2003
No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infectionsD C Kilpatrick, L A McLintock, E K Allan, et al.
Leukemia|December 2, 2015
Mtss1 is a critical epigenetically regulated tumor suppressor in CMLM Schemionek, O Herrmann, M M Reher, et al.
Leukemia|January 12, 2020
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual diseaseG A Horne, J Stobo, C Kelly, et al.
Kidney International|July 22, 2011
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal TrialMichael V Rocco, Robert S Lockridge, Gerald J Beck, et al.
Pageof 4